高表达OAZI-1的小鼠乳腺癌4T1细胞诱导抗肿瘤免疫应答的实验研究

目的在细胞和实验动物水平上分析高表达OAZI-1对小鼠乳腺癌4T1细胞诱导抗肿瘤免疫应答的影响。方法 RT-PCR和Western blot用于鉴定高表达OAZI-1的4T1细胞(4T1/OAZI-1);流式细胞仪检测Mφ下同和DC对4T1细胞的吞噬率以及成熟DC标志性表面分子的表达水平;ELISA检测细胞培养上清和小鼠血清中IFN-γ和TNF-α含量。用4T1/OAZI-1和4T1/3.1对照细胞分别接种Balb/c小鼠后,观察接种瘤的生长状况及荷瘤小鼠的生存期。结果 1)成功构建OAZI-1高表达的4T1/OAZI-1细胞株;2)M?和DC对4T1/OAZI-1细胞的吞噬率(10.8%,58.4%)显著高于对照细胞(6.3%,19.6%);3)将DC与4T1/OAZI-1共孵育后,CD40、CD80和CD86(成熟DC细胞表面标志分子)表达阳性的DC比率(62.8%、77.9%和75.1%)显著高于和对照细胞共孵育的DC(43.9%、57.5%和49.6%);4)将4T1/OAZI-1活化的DC与Balb/c小鼠脾淋巴细胞共孵育后,细胞培养上清中IFN-γ含量(28.7 pg/ml)显著高于对照细胞(19.4 pg/ml);5)将4T1/OAZI-1和4T1/3.1细胞分别接种Balb/c小鼠右前肢腋窝皮下,小鼠体内4T1/OAZI-1接种瘤的生长速度显著低于对照细胞接种瘤,其生存期和血清TNF-α和IFN-γ水平也明显高于接种对照细胞的小鼠。结论高表达OAZI-1的小鼠乳腺癌4T1细胞能更有效地被抗原提呈细胞识别、吞噬并诱导T淋巴细胞活化与成熟,诱导机体的抗肿瘤免疫应答,抑制接种瘤在动物体内的生长。     

高表达OAZI-1的小鼠黑色素瘤B16-F1细胞能有效活化小鼠抗原提呈细胞

目的:在细胞水平上分析高表达OAZI-1的小鼠B16-F1细胞能否活化抗原提呈细胞,促进抗原提呈细胞对肿瘤的吞噬以及抗原递呈作用。方法:转染重组质粒后,用RT-PCR和Western blot技术筛选获得高表达OAZI-1的小鼠黑色素瘤B16-F1肿瘤细胞(B16/OAZI-1),同时构建转染空载体质粒p CDNA3.1(+)的小鼠黑色素瘤B16-F1肿瘤细胞(B16/3.1)用作实验对照。制备BALB/c小鼠腹腔巨噬细胞、脾淋巴细胞和骨髓来源的树突状细胞(DC),将B16/OAZI-1和B16/3.1分别与小鼠腹腔巨噬细胞和DC按照1∶5和1∶1的细胞个数比例混合培养4 h,流式细胞术检测巨噬细胞和DC对肿瘤细胞的吞噬率。将B16/OAZI-1和B16/3.1分别与小鼠DC按照1∶5的细胞个数比例混合培养24 h后,流式细胞术检测DC表面分子CD40、CD80和CD86表达的变化。将经肿瘤细胞活化的DC与小鼠脾淋巴细胞混合培养24 h后,ELISA检测细胞上清中IFN-γ的含量。结果:巨噬细胞和DC对B16/OAZI-1细胞吞噬率分别为24.7%和53.9%,与B16/3.1细胞(8.2%和13.8%)相比有较显著性差异。与B16/3.1细胞相比,DC细胞与B16/OAZI-1细胞混合培养24 h后,成熟DC细胞表面分子标志CD40、CD80、CD86的表达分别从24.2%、20.8%和16.4%增加到46.8%、32.5%和36.1%(P0.05);经B16/OAZI-1细胞活化的DC与小鼠脾淋巴细胞混合培养后,细胞上清中IFN-γ的含量为32.9 pg/ml,与B16/3.1细胞处理的DC相比(15.1 pg/ml)有显著性差异(P0.05)。结论:高表达OAZI-1的肿瘤细胞能更有效地被巨噬细胞和DC细胞吞噬,且这一过程能诱导DC细胞成熟活化,成熟的DC细胞将肿瘤抗原递呈给T淋巴细胞并诱导T淋巴细胞活化,从而激活机体抗肿瘤免疫应答。     

B7-1/B7-H1相对比例变化对Hsp70-肽复合物抗肿瘤免疫效应的影响

目的：探讨Hsp7肽复合物对B7-1／B7-H1相对比例的影响及真核表达可溶性PD-1(sPD-1)对Hsp70-肽复合物抗肿瘤作用的影响。方法：通过RT-PCR和半定量PCR技术检测Hsp70-肽复合物体外刺激和体内免疫对小鼠脾细胞正调控共刺激分子B7-1和抑制性共刺激分子B7-H1及其受体PD-1表达的影响；体内转染表达sPD-1后，观察Hsp70-肽复合物免疫小鼠的肿瘤生长以及脾淋巴细胞毒性的变化。结果：基因表达检测表明．Hsp70-肽复合物体外刺激的小鼠脾细胞B7-1 mRNA和B7-H1 mRNA的水平随时问而变化，B7-1／B7-H1比值随刺激时间而增高；Hsp70-肽复合物体内免疫小鼠后期脾细胞B7-1表达下降，B7-H1及其受体PD-1表达上调，B7-1／B7-H1比值逆转；体内表达sPD-1可显著增强和延长Hsp70-肽复合物的抑瘤效果；体内表达sPD-1可提高Hsp70-肽复合物免疫的荷瘤小鼠脾细胞的杀伤率。结论：Hsp70-肽复合物的刺激引起共刺激分子B7-1和B7-H1表达的变化，B7-1／B7-H1的比例与激活效应相关，sPD-1通过阻抑B7-H1／PD-1途径、上调B7-1／B7-H1比例，可增强免疫应答，提高Hsp70-肽复合物特异性免疫治疗肿瘤的效应。     

体外扩增的Treg细胞抑制NK细胞介导的抗肿瘤免疫

目的研究CD4+CD25+调节性T细胞(regulatory T cells,Tregs)对NK细胞肿瘤杀伤力的影响及Treg细胞介导的抗肿瘤免疫抑制的机制;初步探讨过继输注NK细胞逆转Treg细胞介导的抗肿瘤免疫抑制的作用。方法免疫磁珠分离法(MACS)分离得小鼠脾脏Treg细胞及NK细胞,用流式细胞术检测其纯度。以CD3/CD28单克隆抗体磁珠和重组小鼠白介素2(rm IL-2)联合刺激体外扩增Treg细胞,重组小鼠白介素15(rm IL-15)、rm IL-2以及氢化可的松联合刺激体外扩增NK细胞。将扩增后Treg细胞及NK细胞按不同比例混合淋巴细胞培养,MTT比色法检测NK细胞的杀伤活性。将B16-F10小鼠黑色瘤细胞输注至Balb/c小鼠体内建立肺移植瘤模型[1],将荷瘤小鼠分为4组:A组单独接种B16-F10小鼠黑色瘤细胞;B组接种Treg细胞+B16-F10黑色素瘤细胞;C组接种B16-F10黑色素瘤细胞+NK细胞;D组接种Treg细胞+B16-F10黑色素瘤细胞+NK细胞。MTT比色法测定各实验组小鼠脾脏NK细胞的杀伤活性,并比较不同处理组小鼠肺部肿瘤结节数目。结果体外扩增后的Treg细胞对新鲜分选及扩增后的NK细胞活性均具有明显抑制作用(P0.05),且抑制作用呈剂量依赖关系;A组荷瘤小鼠NK细胞活性低于正常小鼠,且B组荷瘤小鼠NK细胞活性较A组进一步降低(P0.05);D组荷瘤小鼠NK细胞活性高于A组和B组荷瘤小鼠,但仍低于正常小鼠组(P0.05)。B组荷瘤小鼠肺部移植瘤数目(105.33±10.97)较A组明显增多(17±4.58)(P0.01);C组荷瘤小鼠肺部移植瘤数目(2.00±1.00)较A组(17±4.58)明显减少(P=0.037);D组荷瘤小鼠肺移植瘤数目(79.00±8.54)较B组明显降低(105.33±10.97)(P=0.030),但仍高于A组荷瘤小鼠(17±4.58)(P0.001)。结论体内种植肿瘤会抑制机体NK细胞活性;输注体外扩增Treg细胞能够通过抑制NK细胞发挥抗肿瘤免疫抑制;过继输注体外扩增NK细胞能够部分逆转Treg细胞介导的抗肿瘤免疫抑制。     

OAZI-1增强小鼠Melan-A疫苗免疫原性

目的探讨鸟氨酸脱羧酶抗酶抑制剂-1(OAZI-1)能否增强Melan-A疫苗的免疫原性,进而诱导实验动物体内更强的细胞免疫效应。方法构建真核表达质粒pc DNA3.1(-)/OAZI-1、pc DNA3.1(-)/Melan-A及pc DNA3.1(-)/Melan-A-OAZI-1。将真核表达质粒作为基因疫苗免疫BALB/c小鼠,收集小鼠脾脏淋巴细胞及血液,用流式细胞计量术检测淋巴细胞亚群的变化;用乳酸脱氢酶(LDH)释放分析法检测脾淋巴细胞的肿瘤杀伤活性;用ELISA分析法检测血清INF-γ水平。结果成功构建了真核表达质粒pc DNA3.1(-)/OAZI-1、pc DNA3.1(-)/Melan-A及pc DNA3.1(-)/Melan-A-OAZI-1;将真核表达质粒作为基因疫苗免疫小鼠后,小鼠脾脏CD4+T细胞比率显著性升高(P0.05),其中以pc DNA3.1(-)/Melan-A-OAZI-1免疫组和pc DNA3.1(-)/Melan-A免疫组升高更为明显(二者之间无显著性差异);上述3种基因疫苗接种小鼠后,CD8+T细胞比率也显著性升高(p0.05),但以pc DNA3.1(-)/Melan-A-OAZI-1免疫组升高最为显著,与所有其他组相比均有显著性差异(P0.05);用pc DNA3.1(-)/Melan-A-OAZI-1免疫小鼠能显著增加脾淋巴细胞的肿瘤杀伤活性(P0.05);上述3种基因疫苗免疫小鼠后,仅pc DNA3.1(-)/Melan-A-OAZI-1组小鼠血清中INF-γ含量显著性升高(P0.01)。结论 OAZI-1能通过促进肿瘤抗原提呈,增加机体的抗肿瘤免疫能力。     

pcDNA3.1+/MAGE-3 DNA疫苗诱导特异性抗肿瘤免疫应答的实验研究

目的：构建pcDNA3.1+/MAGE-3 DNA疫苗，观察其在小鼠体内诱导特异性抗肿瘤免疫应答的能力。方法： 通过RT-PCR构建重组表达质粒pcDNA3.1+/MAGE-3；以pcDNA3.1+/MAGE-3 DNA疫苗免疫已接种肿瘤细胞的小鼠，每10 d重复免疫1次，共3次，以pcDNA3.1+、PBS为对照。末次免疫后5 d检测血清中MAGE-3抗体滴度、小鼠脾淋巴细胞的细胞毒T细胞（cytotoxic T lymphocytes，CTL）杀伤活性、细胞因子IL-2和IFN-γ的浓度，同时计算抑瘤率。结果： 成功构建了pcDNA3.1+/MAGE-3 DNA疫苗，用此疫苗免疫已接种B16/MAGE-3细胞的小鼠后，能诱导小鼠脾淋巴细胞MAGE-3特异性的杀伤活性，脾细胞培养上清中细胞因子IL-2和IFN-γ的浓度明显增高，血清中抗MAGE-3抗体在1∶20滴度时阳性，肿瘤生长被显著抑制，与pcDNA3.1+组、PBS组相比，差异显著（P＜0.01）。结论： 成功构建了pcDNA3.1+/MAGE-3 DNA疫苗，该疫苗在小鼠体内既能激活CTL杀伤活性和CD4+ T细胞活性，又能激活体液免疫反应，从而诱导出特异性的抗肿瘤免疫应答。     

结核杆菌H37Ra免疫小鼠后脾淋巴细胞的杀伤活性及免疫机制的研究

目的探讨结核杆菌H37Ra免疫小鼠后,产生特异性的脾淋巴细胞杀伤活性及其免疫机制。方法(1)分别以结核杆菌H37Ra、BCG和PBS免疫小鼠后第30天及第60天,分离各组小鼠脾淋巴细胞作为效应细胞,以表达Ag85B分泌蛋白的Sp2/0细胞为靶细胞,用MTT比色法检测免疫小鼠脾淋巴细胞的杀伤率;(2)在免疫后第60天,小鼠脾淋巴细胞经PPD刺激后,以RT-PCR法检测穿孔素mRNA及颗粒酶BmRNA的表达。结果(1)结核杆菌H37Ra组脾淋巴细胞的杀伤率明显高于PBS对照组(P<0.05),略高于BCG组;(2)H37Ra组和BCG组穿孔素、颗粒酶mRNA的表达量均显著高于PBS组(P<0.05),H37Ra组穿孔素mRNA的表达量显著高于BCG组(P<0.05),但颗粒酶BmRNA的表达量两组无差异。结论结核杆菌H37Ra免疫小鼠后,能增强脾淋巴细胞的杀伤活性,其机制可能与增加穿孔素、颗粒酶B的表达有关。     

阳离子脂质体介导IL-15基因治疗小鼠肺转移模型的实验研究

目的:用阳离子脂质体(CL)包裹pcDNA3.1-IL15制备阳离子脂质体质粒DNA复合物CL-IL15,观察其抗小鼠B16-F10肺转移瘤的治疗作用,并初步探讨其作用机制。方法:构建hIL-15真核表达载体,测定脂质体-质粒DNA复合物的最佳包封率;将该复合物转染CHO-K1细胞株,West-ern blott检测体外转染条件下IL-15蛋白的表达情况,MTT法检测细胞转染上清对CTLL-2细胞株的增殖刺激作用;建立B16-F10小鼠黑色素瘤肺转移模型,尾静脉给药,每隔1 d给药1次,共6次,治疗结束24 h后观察各组肿瘤肺转移情况;LDH释放法(乳酸脱氢酶释放法)检测脾淋巴细胞的杀伤作用,冰冻切片免疫荧光法观察NK细胞对肿瘤组织的浸润。结果:成功构建hIL-15表达载体,并验证其与阳离子脂质体的质量比为1∶5时,包裹后形成的复合物具有较好的包封率;可以在体外有效转染并表达具生物活性的分泌型IL-15蛋白;CL-IL15复合物治疗小鼠肿瘤肺转移模型,可以显著减少肿瘤肺转移结节数目,提高脾细胞对肿瘤细胞杀伤活性(P<0.05),增加NK细胞在肿瘤组织中的浸润比例。结论:阳离子脂质体质粒DNA复合物CL-IL15可有效地抑制小鼠B16-F10肺转移瘤,其作用机制可能与IL-15诱导脾细胞对肿瘤细胞的杀伤、激活NK(natural killer)细胞对肿瘤组织的浸润等机制有关。     

腺病毒编码人TRP2修饰DC诱发抗小鼠黑色素瘤免疫的研究

目的比较腺病毒载体(Ad)介导人和小鼠酪氨酸酶相关蛋白2(tyrosinase-relatedpro-tein2,TRP2)修饰小鼠骨髓来源的树突状细胞(BM-DC)诱发抗小鼠黑色素瘤免疫的差异。方法Ad编码人或小鼠TRP2(AdhTRP2或AdmTRP2)体外感染小鼠BM-DC并体内皮下免疫C57BL/6小鼠,7d后取出被免疫小鼠脾细胞行体内细胞毒性T淋巴细胞杀伤试验(invivoCTL)和细胞内IFN-γ染色(ICS)分析CTL的杀伤活性和IFN-γ的产生;或给免疫后小鼠皮下接种小鼠B16.F10黑色素瘤细胞,观察荷瘤小鼠的成活情况。结果invivoCTL和ICS分析显示,AdhTRP2/BM-DC免疫小鼠,其6hCTL杀伤率为(98.7±1.2)%,IFN-γ产生的CD8+T细胞占总CD8+T细胞的(1.25±0.21)%;而AdmTRP2/BM-DC免疫的小鼠,其6hCTL杀伤率和产生IFN-γ的CD8+T细胞比例分别为(28.6±6.3)%和(0.24±0.06)%。荷瘤试验表明,AdhTRP2/BM-DC免疫小鼠后1周皮下接种106B16.F10细胞,观察3个月100%的小鼠无瘤生长;而接种5×104B16.F10细胞至AdmTRP2/BM-DC免疫1周的小鼠,3个月后小鼠成活率仅为40%。结论Ad介导异种(人)TRP2较自身(小鼠)TRP2修饰的BM-DC更为有效地打破肿瘤免疫耐受、诱导强烈的抗黑色素瘤免疫反应,是一种高效的以DC为基础的肿瘤疫苗。     

接种卡介苗对热休克蛋白65-MUC1抗原肽融合蛋白抑瘤作用的影响

目的：探讨接种卡介苗对热休克蛋白65-MUC1抗原肽融合蛋白（HSP65-MUC1）所激发的抑瘤作用的影响。方法：给经卡介苗免疫后产生HSP65抗体的小鼠注射HSP65-MUC1融合蛋白3次，然后给小鼠接种MUC1阳性的B16肿瘤细胞，观察HSP65-MUC1融合蛋白对MUC1阳性的B16肿瘤细胞在已产生HSP65抗体的小鼠体内生长的抑制作用。结果：HSP65-MUC1能够显著抑制MUC1阳性的B16肿瘤细胞在已产生HSP65抗体小鼠体内的生长，HSP65-MUC1组小鼠的肿瘤重量和体积显著地低于PBS组。结论：接种卡介苗并不影响HSP65-MUC1所激发的对MUC1阳性B16肿瘤细胞生长的抑制作用。     

布鲁氏菌OMP31 T-B联合表位抗原的免疫应答分析

目的：研究OMP31表位的抗原性和免疫应答特点,为布鲁氏菌表位疫苗的研制奠定基础。方法：利用生物信息软件筛选OMP31 T-B联合优势抗原表位,进一步合成肽段。用OMP31肽段免疫BALB/c小鼠,采用ELISA检测小鼠血清中特异性IgG1和IgG2a抗体水平,ELISPOT检测脾淋巴细胞中IFN-γ阳性的T淋巴细胞活化情况。结果：用OMP31合成肽段免疫BALB/c小鼠4次后,小鼠血清中IgG1和IgG2a抗体水平升高,小鼠脾淋巴细胞集落形成单元（SFU）增高。结论：OMP31 T-B联合表位抗原能增强小鼠Th1免疫应答和体液免疫应答,可以作为布鲁氏菌病的候选疫苗。     

柯萨奇病毒B3 VP1蛋白、rAd/VP1和pcDNA3/VP1的免疫效果比较

目的 观察柯萨奇病毒B3(Coxsackievirus B3,CVB3)衣壳蛋白VP1、表达VP1蛋白的重组腺病毒rAd/VP1和重组质粒pcDNA3/VP1的免疫效果.方法 用原核细胞表达VP1蛋白并纯化、扩增重组腺病毒rAd/VP1,扩增并提取真核表达质粒pcDNA3/VP1.BALB/c小鼠随机分为4组,每组18只,分别在股四头肌注射VP1蛋白、rAd/VP1、pcDNA3/VP1和PBS.VP1蛋白组和pcDNA3/VP1组免疫3次,间隔3周;rAd/VP1组免疫2次,间隔2周.VP1蛋白、pcDNA3/VP1和rAd/VP1每次每只注射剂量分别为50μg、100μg和1.2×107PFU.用ELISA法和微量中和试验法检测各次免疫后血清CVB3特异性IgG抗体和中和抗体滴度;末次免疫后3周,CCK-8法检测脾脏淋巴细胞的CTL杀伤活性;用致死量CVB3攻击小鼠后,检测血中病毒滴度并观察动物的存活情况.结果 VP1蛋白组血清特异性IgG抗体和中和抗体滴度明显高于其他实验组(P＜0.05),而脾脏淋巴细胞CTL杀伤活性低于rAd/VP1组(P＜0.05);致死量病毒攻击后,VP1蛋白组血中病毒滴度低于pcDNA3/VP1和rAd/VP1组(P＜0.05),生存率明显高于这两组(P＜0.05).结论 VP1蛋白疫苗能诱导较高水平的体液免疫应答,对动物有明显的免疫保护作用,免疫效果优于质粒pcDNA3/VP1和重组腺病毒rAd/VP1.

Abstract：

Objective To compare the immune effects of Coxsackievirus B3 (CVB3) capsid protein VP1 expressed bacterially, recombinant adenovirus rAd/VP1 and recombinant plasmid pcDNA3/VP1which express VP1 protein in mice. Methods After expressed in prokaryotic cells, VP1 protein was purified. Recombinant adenovirus rAd/VP1 and recombinant plasmid pcDNA3/VP1 were amplified and extracted. Six to 8-week-old, male BALB/c mice were divided into four groups randomly. Each group contained 18 mice. The mice of pcDNA3/VP1 group or VP1 protein group were immunized intramuscularly with three injections at three weeks apart, of recombinant plasmid pcDNA3/VP1 at a dose of 100 μg/mouse or recombinant protein VP1 at a dose of 50 μg/mouse. The mice of rAd/VP1 group were immunized intramuscularly twice at two weeks interval with rAd/VP1 at a dose of 1.2 × 107 PFU. The control group was mock-immunized with 100 μl of PBS intramuscularly. Mice were bled from the retroorbital sinus plexus every two weeks after each immunization. ELISA and micro-neutralization test were used to detect levels of CVB3-specific IgG antibody and neutralizing antibody titers in the sera of immunized mice. Three weeks after the last immunization, the cytotoxic T lymphocyte(CTL) killing activity of spleen lymphocytes was detected with CCK-8 assay. Subsequently, virus titers in the sera of immunized mice were determined by the 50% cell culture infective dose( CCID50 ) assay on HeLa cell monolayers and percentage of animals surviving were observed after lethal CVB3 attack over a period of 21 days. Results The titers of specific IgG antibody and neutralizing antibody in sera of VP1 protein immunized mice were higher than other groups( P ＜0.05 ). While CTL killing activity of spleen lymphocytes of VP1 protein immunized mice was lower than mice in rAd/VP1 group( P ＜0. 05). Virus titers in sera of VP1 protein immunized mice were lower than the mice in pcDNA3/VP1 or rAd/VP1 groups ( P ＜ 0.05 ), while survival rate was significantly higher than these two groups ( P ＜ 0.05 ).Conclusion VP1 protein induced higher level of humoral immune response and acquired obvious immune protection effects in mice. The immunizing potency of VP1 protein vaccine surpassed plasmid pcDNA3/VP1or recombinant adenovirus rAd/VP1. It appeared to be a promising candidate among the three different vaccines.     

抗人F1-F0 ATP合成酶beta亚基单抗的制备及其抗肿瘤活性研究

目的：制备鼠抗人F1-F0ATP合成酶beta亚基（hATP5B）单抗,并对其特异性和抗肿瘤活性进行研究。方法：以原核表达人hATP5B免疫BALB/c小鼠,通过杂交瘤技术,筛选分泌抗hATP5B单抗的杂交瘤细胞株。采用Protein A亲和层析法纯化抗体腹水,SDS-PAGE检测纯化产物纯度。利用Western blot、细胞免疫荧光对其特异性进行鉴定,并通过抑制乳腺癌细胞MCF-7及其耐药株MCF-7/Adr表面ATP生成,细胞毒性实验进行抗肿瘤活性研究。结果：获得一株稳定表达抗hATP5B单抗的杂交瘤细胞株Mab3B8,Western blot和细胞免疫荧光结果表明,该抗体与乳腺癌MCF-7及其耐药细胞MCF-7/Adr细胞天然抗原结合；可明显抑制MCF-7及其耐药株MCF-7/Adr细胞膜表面ATP合成；与化疗药物多柔比星（曾用名：阿霉素）联合作用,可降低化疗药物多柔比星对肿瘤细胞的IC50。结论：成功建立了一株可特异性识别天然hATP5B的单抗,有阻断肿瘤细胞膜表面ATP合成活性并可明显增强MCF-7及其耐药株MCF-7/Adr细胞对多柔比星敏感性的作用。此项研究对膜表达F1-F0ATP合成酶功能探讨及肿瘤治疗研究都具有重要意义。     

IL-18和HIV-1 gag-gp120嵌合基因DNA疫苗联合免疫小鼠的免疫应答

目的 :探讨IL 18和HIV 1gag gp12 0嵌合基因的DNA疫苗联合免疫小鼠的免疫应答。方法 :构建含IL 18的真核表达质粒pVAXIL18,将他与表达HIV 1gag gp12 0嵌合基因的核酸疫苗质粒pVAXGE共同肌注免疫BALB/c小鼠 ,检测免疫小鼠脾特异性CTL杀伤活性和血清抗体滴度。结果 :联合免疫组小鼠脾特异性CTL杀伤活性和血清抗体水平均显著高于单独免疫组 (P <0 .0 5 ) ,空白质粒对照组 (P <0 .0 1)和PBS对照组 (P <0 .0 1)。结论 :IL 18和HIV 1gag gp12 0嵌合基因的DNA疫苗联合免疫可诱导小鼠产生特异性细胞和体液免疫 ,且IL 18发挥了免疫佐剂的作用。     

双歧杆菌完整肽聚糖对重组乙肝表面抗原细胞免疫应答的影响

目的:探讨双歧杆菌完整肽聚糖(BWPG)对重组乙肝表面抗原(rHBsAg)诱导细胞免疫应答的影响。方法:以BWPG作为rHBsAg的佐剂免疫BALB/c小鼠,观察免疫小鼠的生长状态及中枢淋巴器官的发育情况,检测NK细胞和CTL杀伤活性的变化,脾淋巴细胞的增殖和细胞因子的产生。结果:免疫小鼠未出现可见的毒副反应,胸腺和脾脏组织呈增生状态,脾脏NK细胞和CTL的杀伤活性增强,脾淋巴细胞体外增殖活跃,细胞因子产生增多。结论:BWPG能促进中枢淋巴器官增生,增强机体对rHBsAg的细胞免疫应答。     

Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine

Groups of mice were immunized either subcutaneously or intranasally with purified Brucella melitensis lipopolysaccharide (LPS) or with LPS as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (LPS-GBOMP). Control mice were inoculated with sterile saline. Two doses of vaccine were given 4 weeks apart. Mice were challenged intranasally with virulent B. melitensis strain 16M 4 weeks after the second dose of vaccine. Sera, spleens, lungs, and livers of mice were harvested 8 weeks after challenge. The bacterial loads in the organs were determined by culture on brucella agar plates. Protective efficacy was determined by comparing the clearance of bacteria from organs of immunized mice with the clearance of bacteria from organs of control mice. At 8 weeks postchallenge there was significant protection from disseminated infection of spleens and livers of mice intranasally immunized with either vaccine compared to infection of control mice (P < 0.01). There was no significant difference in clearance of bacteria from the lungs of immunized mice and control mice. However, mice immunized subcutaneously with either LPS or LPS-GBOMP vaccine showed significant protection against infection of the spleen (P < 0.001), liver (P < 0.001), and lungs (P < 0.05). These results show that intranasal immunization of mice with either vaccine provided significant protection against disseminated infection of the spleen and liver but subcutaneous immunization of mice with the vaccines conferred significant protection against infection of the spleen, liver, and lungs.     

The influence of immunization of Syrian hamsters with tumor cells treated with glutaraldehyde on transplantation immunity and the cytotoxic effect of lymphocytes on polyoma tumor cells.

The influence of glutaraldehyde on polyoma tumor cells was studied in syngeneic Syrian hamsters, which were inoculated with glutarldhehyde-treated cells. Sera from carriers of the tumor, immunized hamsters and healthy animals inhibited in vitro cytotoxicity of sensitized lymphocytes (spleen cells) for tumor cells. If healthy animals were inoculated subcutaneously with spleen cells from immunized hamsters together with tumor cells, tumor growth was inhibited (in Winn's test) compared with animals not so inoculated and recieving only tumor cells. Cells taking part in immune responses to hamster membrane antigens were demonstrated in vitro by the microcytotoxic test. Lymphocytes from hamsters immunized with polyoma tumor cells fixed with glutaraldehyde against polyoma tumor cells were cytotoxic for target cells provided the ratio of attacking to target cells was 50:1 or higher.     

表达HIV-1 gag-gp120嵌合基因的DNA疫苗在小鼠体内的免疫应答

目的 :检测表达HIV 1gag gp12 0嵌合基因的DNA疫苗在小鼠体内的免疫应答效果。方法 :将真核表达质粒pVAXGE肌肉注射BALB C小鼠 ,观察免疫小鼠脾T淋巴细胞亚群的数量、特异性CTL杀伤率及小鼠免疫后不同时间点血清中IgG抗体滴度。结果 :重组质粒pVAXGE免疫组小鼠脾淋巴细胞进行了增殖 ,脾特异性CTL杀伤率显著高于对照组 (P <0 0 1) ;小鼠免疫后于第 8周血清抗体达到最高。结论 :表达HIV 1gag gp12 0嵌合基因的DNA疫苗质粒可诱导BALB C小鼠发生免疫应答